United Therapeutics jumps as Tyvaso IPF Phase 3 TETON-1 hits primary endpoint
United Therapeutics shares are surging after the company said its Phase 3 TETON-1 study of nebulized Tyvaso in idiopathic pulmonary fibrosis met the primary endpoint, showing a 130.1 mL benefit in absolute forced vital capacity versus placebo at week 52 (p<0.0001). The readout expands Tyvaso’s potential commercial runway beyond pulmonary hypertension and shifts investor focus to an additional major revenue driver.
1) What’s driving UTHR today
United Therapeutics (UTHR) is rallying after announcing that its Phase 3 TETON-1 trial of nebulized Tyvaso (treprostinil) in idiopathic pulmonary fibrosis (IPF) achieved its primary efficacy endpoint. The company reported superiority over placebo on the change in absolute forced vital capacity (FVC) from baseline to week 52, with a 130.1 mL Hodges–Lehmann estimate (95% CI: 82.2 to 178.1) and p<0.0001. (fr.benzinga.com)
2) Why the result matters for valuation
IPF is a large, chronic specialty market where incremental benefits that preserve lung function can translate into durable utilization and long duration of therapy. Investors are reacting to the prospect that Tyvaso—already a core franchise for United in pulmonary hypertension—could add another sizable indication that expands the addressable patient pool and supports longer-term cash generation.
3) Broader catalyst stack investors are weighing
Today’s move also lands amid a broader momentum backdrop for United’s pulmonary pipeline. Earlier in March 2026, the company reported that its Phase 3 ADVANCE OUTCOMES study of once-daily ralinepag in pulmonary arterial hypertension reduced the risk of clinical worsening by 55% versus placebo (hazard ratio 0.45) and said it plans to submit an NDA in the second half of 2026. (ir.unither.com)
4) What to watch next
Key swing factors from here include the company’s regulatory path and timeline for an IPF filing based on TETON-1, the strength and detail of any upcoming safety/secondary endpoint disclosures, and how management frames the commercial strategy alongside its existing inhaled treprostinil products. Investors will also monitor execution on capital returns after the board authorized a $2.0 billion share repurchase program in March 2026. (edgar.secdatabase.com)